Media coverage about Akebia Therapeutics (NASDAQ:AKBA) has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Akebia Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.5346833384929 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
Several analysts have recently issued reports on AKBA shares. ValuEngine lowered Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, March 13th. Mizuho reissued a “buy” rating and set a $24.00 target price on shares of Akebia Therapeutics in a report on Tuesday, March 13th. BidaskClub lowered Akebia Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, June 18th. Zacks Investment Research lowered Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 19th. Finally, HC Wainwright reduced their target price on Akebia Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Wednesday, June 6th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $21.83.
Shares of AKBA traded up $0.09 during trading hours on Tuesday, hitting $10.79. 401,400 shares of the company were exchanged, compared to its average volume of 428,232. The firm has a market cap of $611.49 million, a P/E ratio of -6.10 and a beta of 1.11. Akebia Therapeutics has a fifty-two week low of $8.93 and a fifty-two week high of $20.25.
Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings data on Wednesday, May 9th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.01. Akebia Therapeutics had a negative return on equity of 47.15% and a negative net margin of 27.48%. The business had revenue of $45.93 million during the quarter, compared to the consensus estimate of $47.80 million. equities analysts anticipate that Akebia Therapeutics will post -2.12 EPS for the current year.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for patients with renal disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease in dialysis and non-dialysis patients.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.